1-YEAR SURVIVAL | 2-YEARS SURVIVAL | 5-YEARS SURVIVAL | |||||
---|---|---|---|---|---|---|---|
Covariate | Hazard ratio (95% CI)* | P Value | Hazard ratio (95% CI)* | P Value | Hazard ratio (95% CI)* | P Value | |
Gender | (male vs. females) | 1.00 (0.61-1.63) | 0.99 | 1.08 (0.75-1.57) | 0.66 | 1.00 (0.75-1.35) | 0.98 |
Age | (per 10 years) | 1.00 (0.98-1.02) | 0.69 | 0.99 (0.98-1.00) | 0.19 | 1.00 (0.99-1.01) | 0.83 |
Duration of Disease | (per year) | 0.94 (0.86-1.04) | 0.22 | 0.93 (0.86-0.99) | 0.03 | 0.97 (0.93-1.01) | 0.16 |
Previous Surgery | (vs. no surgery) | 0.59 (0.33-1.04) | 0.07 | 0.57 (0.38-0.87) | 0.009 | 0.63 (0.45-0.87) | 0.006 |
Previous Chemotherapy | (vs. no chemotherapy) | 1.28 (0.75-2.19) | 0.37 | 1.28 (0.86-1.93) | 0.23 | 1.68 (1.21-2.32) | 0.002 |
Previous Radiation | (vs. no radiation) | 0.63 (0.31-1.31) | 0.22 | 0.75 (0.45-1.25) | 0.27 | 0.93 (0.62-1.39) | 0.72 |
Solitary Metastases | (vs. multiple metastases) | 0.38 (0.11-1.37) | 0.14 | 0.60 (0.22-1.60) | 0.31 | 0.63 (0.29-1.38) | 0.25 |
Liver Metastases | (vs. no liver metastases) | 1.83 (0.68-4.95) | 0.24 | 1.40 (0.68-2.92) | 0.36 | 1.57 (0.88-2.80) | 0.13 |
Bone Metastases | (v. no bone metastases) | 1.59 (0.90-2.81) | 0.11 | 1.18 (0.74-1.87) | 0.49 | 1.38 (0.94-2.01) | 0.10 |
Tumor Uptake Score 2 | (vs. uptake score 1) | 1.47 (0.35-6.14) | 0.60 | 2.10 (0.69-6.42) | 0.19 | 0.77 (0.31-1.92) | 0.58 |
Tumor Uptake Score 3 | (vs. uptake score 1) | 0.51 (0.13-2.09) | 0.35 | 0.85 (0.28-2.61) | 0.78 | 0.40 (0.16-0.98) | 0.05 |
Low Dose [90Y-DOTA]-TOC | (vs. High Dose) | 0.93 (0.19-4.58) | 0.93 | 0.39 (0.13-1.19) | 0.10 | 0.39 (0.16-0.96) | 0.04 |
Intermediate Dose [90Y-DOTA]-TOC | (vs. High Dose) | 0.74 (0.24-2.31) | 0.61 | 0.52 (0.25-1.11) | 0.09 | 0.57 (0.33-0.99) | 0.05 |